Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Comment by HuntNGatheron Mar 20, 2018 11:28am
271 Views
Post# 27746576

RE:Orphan Drug Designation

RE:Orphan Drug DesignationOh Erudite... I am with you on that.
This is apparently very good news and a solid shot in the arm in support of what the TRIL people are doing.  Safe, Effective... all good words.

I too hoped (and still hope) that it will translate into a bump.
But alas, it has lived up to the past performance history in the immediate term.

Bad news .... fall off a cliff.
Good news.... roll down a hill.
Inexplicable anticipation of something in the middle of September....up 20% for a week then recede.

I will continue to bet on this horse until I read about it being on a menu in a bistro somewhere in the Riviera.
But I must admit, I am losing my patience ....if not my sense of humour.

Here's to a return to sanity and normal behaviour..Cheers.


Best HnG
<< Previous
Bullboard Posts
Next >>